{"id":"NCT03314662","sponsor":"Seqirus","briefTitle":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","officialTitle":"A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-17","primaryCompletion":"2017-12-11","completion":"2018-05-17","firstPosted":"2017-10-19","resultsPosted":"2020-07-22","lastUpdate":"2020-07-22"},"enrollment":1778,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza, Human"],"interventions":[{"type":"BIOLOGICAL","name":"MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)","otherNames":[]},{"type":"BIOLOGICAL","name":"MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)","otherNames":[]}],"arms":[{"label":"aQIV","type":"EXPERIMENTAL"},{"label":"aTIV-1","type":"EXPERIMENTAL"},{"label":"aTIV-2","type":"EXPERIMENTAL"}],"summary":"This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.","primaryOutcome":{"measure":"Immunogenicity Endpoint: The Geometric Mean Titer (GMT) and GMT Ratio for the Four Strains Included in the Vaccine, Non-inferiority Analysis.","timeFrame":"Day 22","effectByArm":[{"arm":"aQIV","deltaMin":65.01,"sd":null},{"arm":"aTIV-1","deltaMin":null,"sd":null},{"arm":"aTIV-2","deltaMin":null,"sd":null},{"arm":"aTIV-1/aTIV-2","deltaMin":75.16,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":null},{"comp":"OG000 vs OG001 vs OG002","p":null},{"comp":"OG000 vs OG001 vs OG002","p":null},{"comp":"OG000 vs OG001 vs OG002","p":null}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":20,"countries":["United States"]},"refs":{"pmids":["31635976"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":888},"commonTop":["Pain","Redness","Swelling","Fatigue","Headache"]}}